CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+1.95%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$328M
AUM Growth
+$328M
(+27%)
Cap. Flow
+$61.8M
Cap. Flow
% of AUM
18.82%
Top 10 Holdings %
Top 10 Hldgs %
55.88%
Holding
38
New
12
Increased
9
Reduced
5
Closed
11
Top Buys
| 1 |
Merck
MRK
|
$21.7M |
| 2 |
Amgen
AMGN
|
$20.1M |
| 3 |
Kenvue
KVUE
|
$17.5M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$15M |
| 5 |
Cytokinetics
CYTK
|
$12.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$24.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$15.7M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$12.2M |
| 4 |
Halozyme
HALO
|
$10.4M |
| 5 |
Exelixis
EXEL
|
$9.46M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Consumer Staples | 5.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.5M | 6.8% |
273,533
+98,533
| +56% | +$8.11M |
|
|
2
Merck
MRK
$210B
| $21.7M | 6.56% |
+175,600
| New | +$21.7M |
|
3
Gilead Sciences
GILD
$140B
| $20.1M | 6.07% |
292,959
+27,523
| +10% | +$1.89M |
|
|
4
Amgen
AMGN
$155B
| $20.1M | 6.06% |
+64,201
| New | +$20.1M |
|
5
Royalty Pharma
RPRX
$15.6B
| $18.3M | 5.51% |
692,300
+280,760
| +68% | +$7.4M |
|
6
Biogen
BIIB
$19.4B
| $17.8M | 5.37% |
76,726
+24,726
| +48% | +$5.73M |
|
|
7
Kenvue
KVUE
$39.7B
| $17.5M | 5.27% |
+960,400
| New | +$17.5M |
|
8
Insmed
INSM
$28.8B
| $15.3M | 4.6% |
227,637
+300
| +0.1% | +$20.1K |
|
9
Legend Biotech
LEGN
$6.41B
| $15.2M | 4.59% |
343,130
+263,300
| +330% | +$11.7M |
|
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $15M | 4.53% |
+365,000
| New | +$15M |
|
11
Teva Pharmaceuticals
TEVA
$21.1B
| $14.8M | 4.47% |
911,900
-223,810
| -20% | -$3.64M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $14.1M | 4.26% |
89,379
-5,000
| -5% | -$790K |
|
|
13
Cytokinetics
CYTK
$4.23B
| $12.8M | 3.87% |
+236,900
| New | +$12.8M |
|
14
BioCryst Pharmaceuticals
BCRX
$1.74B
| $12.2M | 3.68% |
1,975,298
-130,161
| -6% | -$804K |
|
15
CRISPR Therapeutics
CRSP
$4.71B
| $10.9M | 3.29% |
201,497
+81,312
| +68% | +$4.39M |
|
16
Arcellx
ACLX
$3.85B
| $10.3M | 3.12% |
187,000
+80,000
| +75% | +$4.42M |
|
|
AVDL
17
Avadel Pharmaceuticals
AVDL
$1.43B
| $10.3M | 3.11% |
733,001
+191,075
| +35% | +$2.69M |
|
18
Harmony Biosciences
HRMY
$2.12B
| $8.92M | 2.69% |
+295,771
| New | +$8.92M |
|
19
Avantor
AVTR
$9.18B
| $8.48M | 2.56% |
+400,000
| New | +$8.48M |
|
20
Vera Therapeutics
VERA
$1.38B
| $8.32M | 2.51% |
+230,000
| New | +$8.32M |
|
21
BridgeBio Pharma
BBIO
$9.89B
| $7.9M | 2.38% |
+311,700
| New | +$7.9M |
|
22
Ionis Pharmaceuticals
IONS
$6.79B
| $7.63M | 2.3% |
160,166
-129,200
| -45% | -$6.16M |
|
23
Enliven Therapeutics
ELVN
$1.2B
| $5.21M | 1.57% |
+222,985
| New | +$5.21M |
|
24
Pfizer
PFE
$141B
| $5.18M | 1.56% |
+185,200
| New | +$5.18M |
|
25
Evolus
EOLS
$494M
| $5.05M | 1.52% |
+465,300
| New | +$5.05M |
|